PLCB1

Across TCGA pan-cancer cohorts, PLCB1 mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated PLCB1 data layer compared with 24 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PLCB1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLCB1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where PLCB1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.350	0.715	.002	33	view →
PDAC	OS	Median	II,III,IV	0.964	0.701	.003	25	view →
LSCC	OS	Median	All	0.921	1.000	.010	18	view →
CCRCC	OS	Median	IV	0.785	0.123	.009	17	view →
COAD	DFS	Median	All	1.000	0.930	.037	12	view →
UCEC	DFS	Quartile	III,IV	0.340	1.000	.027	6	view →
GBM	DFS	Tertile	All	0.853	0.669	.023	4	view →
HNSC	OS	Median	III,IV	0.946	1.000	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

PLCB1–LUAD (DFS)

Open the LUAD breakdown →